Veverimer

Summary

Veverimer (CHEMBL4298196) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including acidosis disorder and renal osteodystrophy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298196
Name	Veverimer
Type	Small molecule
Max phase	3

Also known as: TRC-101, TRC101, Veverimer, Veverimere, Veverimero, VEVERIMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acidosis disorder	3	MONDO:0006022	EFO:1000014
renal osteodystrophy	1	MONDO:0006946	EFO:1001152
renal tubular acidosis	1	MONDO:0001909	MONDO:0001909

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07355062	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
NCT03317444	PHASE3	COMPLETED	Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
NCT03390842	PHASE3	COMPLETED	Long-term Safety Extension to Study TRCA-301
NCT03710291	PHASE3	TERMINATED	Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
NCT02809183	PHASE1/PHASE2	COMPLETED	Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
NCT07473713	PHASE1	RECRUITING	Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).